Recruiting
Phase 1
Phase 2

Study of AR-14034 in Participants With Neovascular Age-Related Macular Degeneration (nAMD)

Sponsor:

Aerie Pharmaceuticals

Code:

NCT05769153

Conditions

Neovascular Age-related Macular Degeneration (nAMD)

Eligibility Criteria

Sex: All

Age: 50+

Healthy Volunteers: Not accepted

Interventions

AR-14034 SR implant lower dose

Aflibercept Injection

Sham procedure

AR-14034 SR implant higher dose

Study Details

Eligibility Criteria

Study Design

Interventions and Outcome Measures

Central Contacts and Locations

More Information